Clinical Trials Logo

Clinical Trial Summary

Early Access Programme to provide treatment access to moxetumomab pasudotox for eligible patients with relapsed/refractory hairy cell leukemia


Clinical Trial Description

Multicentre Early Access Programme, designed to provide treatment access to moxetumomab pasudotox for eligible patients with relapsed/refractory hairy cell leukemia who are at least 18 years of age, have adequate organ function and are Pseudomonas-immunotoxin naïve. Patients will be administered moxetumomab pasudotox on Days 1, 3 and 5 of each 28-day cycle until documentation of CR or for up to 6 cycles, progressive disease (PD), initiation of alternate therapy or unacceptable toxicity. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03501615
Study type Expanded Access
Source AstraZeneca
Contact
Status Approved for marketing
Phase

See also
  Status Clinical Trial Phase
Recruiting NCT05537766 - Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies Phase 2